Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 420

1.

Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society.

Sholl LM, Aisner DL, Allen TC, Beasley MB, Borczuk AC, Cagle PT, Capelozzi V, Dacic S, Hariri L, Kerr KM, Lantuejoul S, Mino-Kenudson M, Raparia K, Rekhtman N, Roy-Chowdhuri S, Thunnissen E, Tsao MS, Yatabe Y; Members of Pulmonary Pathology Society.

Arch Pathol Lab Med. 2016 Apr;140(4):341-4. doi: 10.5858/arpa.2015-0506-SA. Epub 2016 Jan 18.

PMID:
26780537
2.

A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.

Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, West WW, Wu H, Roden AC, Fujimoto J, Yu H, Anders R, Kowalewski A, Rivard C, Rehman J, Batenchuk C, Burns V, Hirsch FR, Wistuba II.

JAMA Oncol. 2017 Aug 1;3(8):1051-1058. doi: 10.1001/jamaoncol.2017.0013.

3.

Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.

Kerr KM, Nicolson MC.

Arch Pathol Lab Med. 2016 Mar;140(3):249-54. doi: 10.5858/arpa.2015-0303-SA. Review.

PMID:
26927720
4.

Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.

Rebelatto MC, Midha A, Mistry A, Sabalos C, Schechter N, Li X, Jin X, Steele KE, Robbins PB, Blake-Haskins JA, Walker J.

Diagn Pathol. 2016 Oct 8;11(1):95.

5.

Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?

Chae YK, Pan A, Davis AA, Raparia K, Mohindra NA, Matsangou M, Giles FJ.

Clin Lung Cancer. 2016 Sep;17(5):350-361. doi: 10.1016/j.cllc.2016.03.011. Epub 2016 Apr 6. Review.

PMID:
27137346
6.

Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer.

Rehman JA, Han G, Carvajal-Hausdorf DE, Wasserman BE, Pelekanou V, Mani NL, McLaughlin J, Schalper KA, Rimm DL.

Mod Pathol. 2017 Mar;30(3):340-349. doi: 10.1038/modpathol.2016.186. Epub 2016 Nov 11.

7.

The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy.

Villaruz LC, Socinski MA.

Clin Pharmacol Ther. 2016 Sep;100(3):212-4. doi: 10.1002/cpt.385. Epub 2016 Jun 3.

8.

Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.

Kim S, Kim MY, Koh J, Go H, Lee DS, Jeon YK, Chung DH.

Eur J Cancer. 2015 Nov;51(17):2698-707. doi: 10.1016/j.ejca.2015.08.013. Epub 2015 Aug 29.

PMID:
26329973
9.

Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?

Kerr KM, Hirsch FR.

Arch Pathol Lab Med. 2016 Apr;140(4):326-31. doi: 10.5858/arpa.2015-0522-SA. Epub 2016 Jan 12.

PMID:
26756647
10.

Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.

Sacher AG, Gandhi L.

JAMA Oncol. 2016 Sep 1;2(9):1217-22. doi: 10.1001/jamaoncol.2016.0639. Review.

PMID:
27310809
11.

Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.

Remon J, Chaput N, Planchard D.

Curr Opin Oncol. 2016 Mar;28(2):122-9. doi: 10.1097/CCO.0000000000000263. Review.

PMID:
26756384
12.

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.

Schmidt LH, Kümmel A, Görlich D, Mohr M, Bröckling S, Mikesch JH, Grünewald I, Marra A, Schultheis AM, Wardelmann E, Müller-Tidow C, Spieker T, Schliemann C, Berdel WE, Wiewrodt R, Hartmann W.

PLoS One. 2015 Aug 27;10(8):e0136023. doi: 10.1371/journal.pone.0136023. eCollection 2015.

13.

PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation.

Cree IA, Booton R, Cane P, Gosney J, Ibrahim M, Kerr K, Lal R, Lewanski C, Navani N, Nicholson AG, Nicolson M, Summers Y.

Histopathology. 2016 Aug;69(2):177-86. doi: 10.1111/his.12996. Epub 2016 Jun 30. Review. Erratum in: Histopathology. 2017 Jan;70(2):318.

14.

Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue.

Dolled-Filhart M, Locke D, Murphy T, Lynch F, Yearley JH, Frisman D, Pierce R, Weiner R, Wu D, Emancipator K.

Arch Pathol Lab Med. 2016 Nov;140(11):1259-1266.

PMID:
27788043
15.

Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer.

Sheffield BS, Fulton R, Kalloger SE, Milne K, Geller G, Jones M, Jacquemont C, Zachara S, Zhao E, Pleasance E, Laskin J, Jones SJ, Marra MA, Yip S, Nelson BH, Gown AM, Ho C, Ionescu DN.

J Histochem Cytochem. 2016 Oct;64(10):587-600. doi: 10.1369/0022155416665338. Epub 2016 Sep 2.

16.
17.

PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies.

Frydenlund N, Mahalingam M.

Hum Pathol. 2017 Aug;66:13-33. doi: 10.1016/j.humpath.2017.06.012. Epub 2017 Jul 8. Review.

PMID:
28694003
18.

Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?

Kerr KM, Tsao MS, Nicholson AG, Yatabe Y, Wistuba II, Hirsch FR; IASLC Pathology Committee.

J Thorac Oncol. 2015 Jul;10(7):985-9. doi: 10.1097/JTO.0000000000000526. Review.

19.

Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N.

Smith J, Robida MD, Acosta K, Vennapusa B, Mistry A, Martin G, Yates A, Hnatyszyn HJ.

Diagn Pathol. 2016 May 18;11(1):44. doi: 10.1186/s13000-016-0494-2.

20.

[PD-L1 expression: An emerging biomarker in non-small cell lung cancer].

Adam J, Planchard D, Marabelle A, Soria JC, Scoazec JY, Lantuéjoul S.

Ann Pathol. 2016 Jan;36(1):94-102. doi: 10.1016/j.annpat.2015.11.004. Epub 2016 Jan 14. French.

PMID:
26778219

Supplemental Content

Support Center